JP2004513076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513076A5 JP2004513076A5 JP2002514095A JP2002514095A JP2004513076A5 JP 2004513076 A5 JP2004513076 A5 JP 2004513076A5 JP 2002514095 A JP2002514095 A JP 2002514095A JP 2002514095 A JP2002514095 A JP 2002514095A JP 2004513076 A5 JP2004513076 A5 JP 2004513076A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- indol
- phenoxy
- pharmaceutical composition
- trifluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 239000003112 inhibitor Substances 0.000 description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- -1 cyclopropylidene Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229960002797 pitavastatin Drugs 0.000 description 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- HIPJZUFYVANNKA-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OC(C)(C)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 HIPJZUFYVANNKA-UHFFFAOYSA-N 0.000 description 2
- NJQKVYQTUIWJEQ-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C=C(OC(C)(C)C(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 NJQKVYQTUIWJEQ-UHFFFAOYSA-N 0.000 description 2
- GWYAJCNLNHXXBS-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 GWYAJCNLNHXXBS-UHFFFAOYSA-N 0.000 description 2
- QEAQRCMOQDLSRU-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C=CC(OC(C)C(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 QEAQRCMOQDLSRU-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940123064 Glycosyl transferase inhibitor Drugs 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940064856 azulfidine Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 2
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950002375 englitazone Drugs 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical class C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003297 glycosyltransferase inhibitor Substances 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960004738 nicotinyl alcohol Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BWTOBMCYVACNJZ-QGZVFWFLSA-N (2r)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)O[C@H](C)C(O)=O)=C1C BWTOBMCYVACNJZ-QGZVFWFLSA-N 0.000 description 1
- XEWADPLLFDGPAT-GOSISDBHSA-N (2r)-2-[3-[2-[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]ethyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CCC=2C=C(O[C@H](C)C(O)=O)C=CC=2)=C1C XEWADPLLFDGPAT-GOSISDBHSA-N 0.000 description 1
- OFCWBJAYEIROGZ-QGZVFWFLSA-N (2r)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(O[C@H](C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-QGZVFWFLSA-N 0.000 description 1
- APRSDJAYLLJNFZ-LJQANCHMSA-N (2r)-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@@H](C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-LJQANCHMSA-N 0.000 description 1
- BWTOBMCYVACNJZ-KRWDZBQOSA-N (2s)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)O[C@@H](C)C(O)=O)=C1C BWTOBMCYVACNJZ-KRWDZBQOSA-N 0.000 description 1
- VIPDVHYKCSTTSQ-INIZCTEOSA-N (2s)-2-[3-[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(C=2C=C(O[C@@H](C)C(O)=O)C=CC=2)=C1C VIPDVHYKCSTTSQ-INIZCTEOSA-N 0.000 description 1
- OFCWBJAYEIROGZ-KRWDZBQOSA-N (2s)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(O[C@@H](C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-KRWDZBQOSA-N 0.000 description 1
- APRSDJAYLLJNFZ-IBGZPJMESA-N (2s)-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-IBGZPJMESA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- ADWNMHCJSZMYGA-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 ADWNMHCJSZMYGA-UHFFFAOYSA-N 0.000 description 1
- XICCHOADKSBRIM-UHFFFAOYSA-N 2-[2-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C(=CC=CC=2)OC(C)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XICCHOADKSBRIM-UHFFFAOYSA-N 0.000 description 1
- SGUDWIZALUVLKT-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OC(C)(C)C(O)=O)=C1C SGUDWIZALUVLKT-UHFFFAOYSA-N 0.000 description 1
- FGVYFLHVBPQNQC-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OCC(O)=O)=C1C FGVYFLHVBPQNQC-UHFFFAOYSA-N 0.000 description 1
- BWTOBMCYVACNJZ-UHFFFAOYSA-N 2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C(=CC=CC=2)OC(C)C(O)=O)=C1C BWTOBMCYVACNJZ-UHFFFAOYSA-N 0.000 description 1
- CPJTXKYXYBHVIM-UHFFFAOYSA-N 2-[2-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1CC(C1=CC(OC(F)(F)F)=CC=C11)=C(C)N1C(=O)C1=CC=C(C=CC=C2)C2=C1 CPJTXKYXYBHVIM-UHFFFAOYSA-N 0.000 description 1
- JBRSATVQAGDEBO-UHFFFAOYSA-N 2-[3-[[1-(2,4-dichlorobenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C(=CC(Cl)=CC=3)Cl)C=2C)=C1 JBRSATVQAGDEBO-UHFFFAOYSA-N 0.000 description 1
- YGIKSALMJUFCTG-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=CC(Cl)=CC=3)C=2C)=C1 YGIKSALMJUFCTG-UHFFFAOYSA-N 0.000 description 1
- CZMXEBXOLTWIEN-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C=C(OCC(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CZMXEBXOLTWIEN-UHFFFAOYSA-N 0.000 description 1
- UZJIHIMYKLEBBQ-UHFFFAOYSA-N 2-[3-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]propanoic acid Chemical compound CC1=C(CC=2C=C(OC(C)C(O)=O)C=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 UZJIHIMYKLEBBQ-UHFFFAOYSA-N 0.000 description 1
- WTIUDROYDYCRCV-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OC(C)(C)C(O)=O)C=CC=2)=C1C WTIUDROYDYCRCV-UHFFFAOYSA-N 0.000 description 1
- VHWYQIHRMGSPNU-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OCC(O)=O)C=CC=2)=C1C VHWYQIHRMGSPNU-UHFFFAOYSA-N 0.000 description 1
- OFCWBJAYEIROGZ-UHFFFAOYSA-N 2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(OC(C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-UHFFFAOYSA-N 0.000 description 1
- APRSDJAYLLJNFZ-UHFFFAOYSA-N 2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(CC=2C3=CC(OC(F)(F)F)=CC=C3N(C(=O)C=3C=C4C=CC=CC4=CC=3)C=2C)=C1 APRSDJAYLLJNFZ-UHFFFAOYSA-N 0.000 description 1
- YAGQPGVXBAGTLQ-UHFFFAOYSA-N 2-[4-[[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]methyl]phenoxy]acetic acid Chemical compound CC1=C(CC=2C=CC(OCC(O)=O)=CC=2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 YAGQPGVXBAGTLQ-UHFFFAOYSA-N 0.000 description 1
- PEADEDULWAZELC-UHFFFAOYSA-N 2-methyl-2-[2-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C12=CC(OC(F)(F)F)=CC=C2N(C(=O)C=2C=C3C=CC=CC3=CC=2)C(C)=C1CC1=CC=CC=C1OC(C)(C)C(O)=O PEADEDULWAZELC-UHFFFAOYSA-N 0.000 description 1
- PZKINEIEKOPLJY-UHFFFAOYSA-N 2-methyl-2-[3-[[2-methyl-1-(naphthalene-2-carbonyl)-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C12=CC(OC(F)(F)F)=CC=C2N(C(=O)C=2C=C3C=CC=CC3=CC=2)C(C)=C1CC1=CC=CC(OC(C)(C)C(O)=O)=C1 PZKINEIEKOPLJY-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VPDHYUHZLMBWFJ-UHFFFAOYSA-N Cc1c(Cc(cccc2)c2OCC(O)O)c2cc(OC(F)(F)F)ccc2[n]1C(c(cc1)ccc1OC)=O Chemical compound Cc1c(Cc(cccc2)c2OCC(O)O)c2cc(OC(F)(F)F)ccc2[n]1C(c(cc1)ccc1OC)=O VPDHYUHZLMBWFJ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22077800P | 2000-07-25 | 2000-07-25 | |
| PCT/US2001/022979 WO2002008188A1 (en) | 2000-07-25 | 2001-07-20 | N-substituted indoles useful in the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513076A JP2004513076A (ja) | 2004-04-30 |
| JP2004513076A5 true JP2004513076A5 (US06525083-20030225-C00031.png) | 2008-05-22 |
Family
ID=22824932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514095A Withdrawn JP2004513076A (ja) | 2000-07-25 | 2001-07-20 | 糖尿病治療で有用なｎ−置換インドール類 |
Country Status (8)
Families Citing this family (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| DE50111751D1 (de) * | 2000-12-21 | 2007-02-08 | Sanofi Aventis Deutschland | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| US7025985B2 (en) * | 2001-05-28 | 2006-04-11 | Kanebo, Ltd. | Dihydroxyphenyl compounds and glucoside compounds thereof |
| JP4531335B2 (ja) * | 2001-05-28 | 2010-08-25 | 花王株式会社 | 脂肪分解促進剤及びそれを含有する痩身用皮膚化粧料、飲食品組成物並びにその作用に基づく痩身方法及び医薬用途 |
| US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| WO2003024395A2 (en) | 2001-09-14 | 2003-03-27 | Tularik Inc. | Linked biaryl compounds |
| US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| TW200305415A (en) * | 2002-03-22 | 2003-11-01 | Novartis Ag | Combination of organic compounds |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| AU2003225027A1 (en) * | 2002-04-16 | 2003-11-03 | Merck And Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| ITMI20021012A1 (it) * | 2002-05-13 | 2003-11-13 | Giovanni Scaramuzzino | Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato |
| EP1388352A1 (en) * | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
| AU2003265681A1 (en) | 2002-08-29 | 2004-03-19 | Merck And Co., Inc. | Indoles having anti-diabetic activity |
| WO2004019869A2 (en) * | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| SI1539746T1 (sl) * | 2002-09-12 | 2007-04-30 | Hoffmann La Roche | Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa |
| DE10300099A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| EP1590336B1 (en) | 2003-01-27 | 2010-12-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US20040248937A1 (en) * | 2003-04-14 | 2004-12-09 | The Institute For Pharmaceutical Discovery Llc | Substituted phenylalkanoic acids for the treatment of diabetes |
| EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
| US20050107387A1 (en) * | 2003-05-13 | 2005-05-19 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders |
| US20060160834A1 (en) * | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
| WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| DE10335449A1 (de) * | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
| DE10337839A1 (de) * | 2003-08-18 | 2005-03-17 | Bayer Healthcare Ag | Indolin-Derivate |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| BRPI0416238A (pt) * | 2003-11-05 | 2007-01-02 | Hoffmann La Roche | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) |
| JP2007509998A (ja) | 2003-11-05 | 2007-04-19 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐｐａｒ活性化剤としてのベンズ環付加された化合物 |
| NZ546444A (en) * | 2003-11-05 | 2009-09-25 | Hoffmann La Roche | Phenyl derivatives as PPAR agonists |
| CN1886133B (zh) | 2003-12-04 | 2010-12-01 | 财团法人卫生研究院 | 吲哚化合物 |
| TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
| JP2007534702A (ja) * | 2004-04-26 | 2007-11-29 | バンダービルト・ユニバーシティ | 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体 |
| US20080076810A1 (en) * | 2004-05-28 | 2008-03-27 | Weiguo Lui | Benzoureas Having Anti-Diabetic Activity |
| NZ551810A (en) * | 2004-05-29 | 2010-09-30 | 7Tm Pharma As | CRTH2 receptor ligands for medicinal uses |
| NZ551405A (en) * | 2004-06-04 | 2009-06-26 | Merck & Co Inc | Pyrazole derivatives, compositions containing such compounds and methods of use |
| CN1980659A (zh) | 2004-07-02 | 2007-06-13 | 默克公司 | 具有抗糖尿病活性的吲哚类 |
| US7625938B2 (en) | 2004-07-22 | 2009-12-01 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| KR20070058471A (ko) | 2004-07-30 | 2007-06-08 | 라보라토리오스 살바트, 에스.에이. | Ｐｐａｒ-감마-조절자로서의 티로신 유도체 |
| EP1799242A4 (en) * | 2004-09-16 | 2009-11-11 | Univ California | TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES |
| JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ｐｐａｒ調節剤およびそのスクリーニング方法 |
| EP1844043A2 (en) * | 2004-11-18 | 2007-10-17 | The Institutes for Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| FR2880887B1 (fr) * | 2005-01-14 | 2009-01-30 | Merck Sante Soc Par Actions Si | Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
| US7834036B2 (en) | 2005-03-04 | 2010-11-16 | Merck Sharp & Dohme Corp | Fused-aromatic compounds having anti-diabetic activity |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
| JP2008542226A (ja) * | 2005-05-24 | 2008-11-27 | ディーエスエム アイピー アセッツ ビー．ブイ． | 炎症性障害の治療のためのリグスチリド誘導体 |
| US7807692B2 (en) | 2005-07-06 | 2010-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic oxazolidinediones and thiazolidinediones |
| AU2006276072A1 (en) | 2005-07-26 | 2007-02-08 | Merck Sharp & Dohme Corp. | Process for synthesizing a substituted pyrazole |
| US20070161006A1 (en) * | 2006-01-10 | 2007-07-12 | Vita Genomics, Inc. | Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma |
| DE602007010420D1 (de) * | 2006-04-11 | 2010-12-23 | Arena Pharm Inc | Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| CN101528222A (zh) | 2006-06-19 | 2009-09-09 | 范德比尔特大学 | 用于诊断性和治疗性靶向cox-2的方法和组合物 |
| CA2663121C (en) | 2006-09-08 | 2016-01-19 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| NZ578296A (en) | 2007-01-26 | 2012-07-27 | Kaneq Pharma Inc | Fused aromatic ptp-1b inhibitors |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| CA2688187C (en) | 2007-05-07 | 2016-10-11 | Merck & Co., Inc. | Method of treament using fused aromatic compounds having anti-diabetic activity |
| US20080319221A1 (en) * | 2007-06-22 | 2008-12-25 | Bernd Junker | Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids |
| US20080319218A1 (en) * | 2007-06-22 | 2008-12-25 | Andreas Haubrich | Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate |
| JP2010538005A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| WO2009032702A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| FR2921366B1 (fr) * | 2007-09-26 | 2009-12-04 | Servier Lab | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE102007054497B3 (de) * | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| AU2010206786A1 (en) | 2009-01-23 | 2011-07-28 | Merck Sharp & Dohme Corp. | Bridged and fused heterocyclic antidiabetic compounds |
| JP2012515782A (ja) | 2009-01-23 | 2012-07-12 | シェーリング コーポレイション | 抗糖尿病性架橋および縮合化合物 |
| AR075051A1 (es) | 2009-02-05 | 2011-03-02 | Schering Corp | Compuestos antidiabeticos que contienen ftalazina |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8552022B2 (en) | 2009-08-13 | 2013-10-08 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| IN2012DN00721A (US06525083-20030225-C00031.png) | 2009-09-02 | 2015-06-19 | Merck Sharp & Dohme | |
| CA2785790A1 (en) | 2010-01-15 | 2011-07-21 | Merck Sharp & Dohme Corp. | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
| EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| EP2605658B1 (en) | 2010-08-18 | 2016-03-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| WO2012058203A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Diazeniumdiolate heterocyclic derivatives |
| WO2012097744A1 (en) | 2011-01-20 | 2012-07-26 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| JO3350B1 (ar) | 2011-03-07 | 2019-03-13 | Merck Sharp & Dohme | مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات |
| EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| WO2012151114A1 (en) | 2011-05-02 | 2012-11-08 | Merck Sharp & Dohme Corp. | Diazeniumdiolate cyclohexyl derivatives |
| BR112013030883A2 (pt) | 2011-06-02 | 2017-10-10 | Intervet Int Bv | composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma condição selecionada do grupo consistindo em obesidade e diabete |
| WO2012173917A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2012178142A1 (en) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Company, Llc | Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| WO2013055606A1 (en) | 2011-10-13 | 2013-04-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| EP3078374B1 (en) | 2011-10-17 | 2019-06-19 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013068328A1 (en) | 2011-11-07 | 2013-05-16 | Intervet International B.V. | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
| WO2013068439A1 (en) | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| WO2013074388A1 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| IN2014DN09640A (US06525083-20030225-C00031.png) | 2012-04-16 | 2015-07-31 | Kaneq Pharma Inc | |
| US9315508B2 (en) | 2012-07-23 | 2016-04-19 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-IV inhibitors |
| US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
| US9717714B2 (en) | 2012-12-19 | 2017-08-01 | Merck Sharp & Dohme Corp. | Spirocyclic CETP inhibitors |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| EP3097101B1 (en) | 2014-01-24 | 2020-12-23 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016018729A1 (en) | 2014-07-29 | 2016-02-04 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| JP7081923B2 (ja) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果 |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| EP3177287B1 (en) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10413593B2 (en) | 2014-10-24 | 2019-09-17 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| JP6895378B2 (ja) | 2015-01-06 | 2021-06-30 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態の処置方法 |
| WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| EP3322420B1 (en) | 2015-07-13 | 2021-12-29 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| US10450309B2 (en) | 2015-11-30 | 2019-10-22 | Merch Sharp & Dohme Corp. | Aryl sulfonamides as BLT1 antagonists |
| WO2017095724A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| US10414774B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
| WO2018034917A1 (en) | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| WO2018057409A1 (en) | 2016-09-20 | 2018-03-29 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders |
| RU2019117958A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
| WO2018107415A1 (en) | 2016-12-15 | 2018-06-21 | Merck Sharp & Dohme Corp. | Hydroxy isoxazole compounds useful as gpr120 agonists |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| WO2020205688A1 (en) | 2019-04-04 | 2020-10-08 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| WO2020236688A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| EP3972589A4 (en) | 2019-05-22 | 2023-04-26 | Merck Sharp & Dohme LLC | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES |
| WO2021041770A1 (en) | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| EP4153596A1 (en) | 2020-05-18 | 2023-03-29 | Merck Sharp & Dohme LLC | Novel diacylglyceride o-acyltransferase 2 inhibitors |
| IL310851A (en) | 2021-08-19 | 2024-04-01 | Merck Sharp & Dohme Llc | Compounds for the treatment of diseases associated with PCSK9 activity |
| TW202404574A (zh) | 2022-06-15 | 2024-02-01 | 美商默沙東有限責任公司 | 用於捕捉介白素-1 β之環狀肽 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3564009A (en) | 1966-01-13 | 1971-02-16 | Sumitomo Chemical Co | Process for producing 1-acylindole derivatives |
| CH605742A5 (en) | 1973-11-29 | 1978-10-13 | Crc Ricerca Chim | 1-Benzoyl-2-methyl-indole derivs. |
| AU4649189A (en) | 1988-11-14 | 1990-06-12 | Upjohn Company, The | Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| JPH0764841B2 (ja) | 1990-10-03 | 1995-07-12 | ファイザー製薬株式会社 | インドール誘導体およびその用途 |
| US5527819A (en) | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
| US5686481A (en) * | 1993-12-21 | 1997-11-11 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| JP3155008B2 (ja) | 1994-07-26 | 2001-04-09 | ファイザー・インコーポレーテッド | セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体 |
| MX9700696A (es) | 1994-07-27 | 1997-04-30 | Sankyo Co | Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos. |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| DE69629341T2 (de) * | 1995-03-09 | 2004-06-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazolderivate |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| WO1998008818A1 (en) | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| CA2322162A1 (en) * | 1998-02-25 | 1999-09-02 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| IL137540A0 (en) | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
| HUP0100757A3 (en) | 1998-02-25 | 2001-11-28 | Genetics Inst Llc Cambridge | Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them |
| JP2002532479A (ja) * | 1998-12-18 | 2002-10-02 | アクシス・ファーマシューティカルズ・インコーポレイテッド | プロテアーゼインヒビター |
-
2001
- 2001-07-20 AU AU2001277056A patent/AU2001277056B2/en not_active Ceased
- 2001-07-20 CA CA002415742A patent/CA2415742A1/en not_active Abandoned
- 2001-07-20 WO PCT/US2001/022979 patent/WO2002008188A1/en active IP Right Grant
- 2001-07-20 JP JP2002514095A patent/JP2004513076A/ja not_active Withdrawn
- 2001-07-20 DE DE60128475T patent/DE60128475T2/de not_active Expired - Fee Related
- 2001-07-20 AU AU7705601A patent/AU7705601A/xx active Pending
- 2001-07-20 EP EP01954836A patent/EP1305285B1/en not_active Expired - Lifetime
- 2001-07-20 AT AT01954836T patent/ATE362468T1/de not_active IP Right Cessation
- 2001-07-25 US US09/912,961 patent/US6525083B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513076A5 (US06525083-20030225-C00031.png) | ||
| JP2003523336A5 (US06525083-20030225-C00031.png) | ||
| JP2006500384A5 (US06525083-20030225-C00031.png) | ||
| US7393960B2 (en) | Indoles having anti-diabetic activity | |
| EP1893582B1 (en) | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | |
| AU2001277056B2 (en) | N-substituted indoles useful in the treatment of diabetes | |
| JP2007502264A5 (US06525083-20030225-C00031.png) | ||
| JP2005502600A5 (US06525083-20030225-C00031.png) | ||
| AU2003256911B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| JP5786034B2 (ja) | 脂質異常症の治療に適したヘテロ環式化合物 | |
| JP2010529203A5 (US06525083-20030225-C00031.png) | ||
| JP2008536947A (ja) | アリールアルキル酸誘導体およびそれらの使用 | |
| JP2007531764A5 (US06525083-20030225-C00031.png) | ||
| JP2008505091A (ja) | 抗糖尿病活性を有するインドール | |
| US20070173434A1 (en) | Antidiabetic oxazolidinediones and thiazolidinediones | |
| US7524882B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| US7629372B2 (en) | Compounds for the treatment of dyslipidemia and other lipid disorders | |
| US20150051144A1 (en) | Compounds for the treatment of dyslipidemia and other diseases | |
| RU2005114373A (ru) | Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов) | |
| JP2009500355A (ja) | 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン | |
| JP2008501027A (ja) | 抗糖尿病活性をもつベンゾ尿素 | |
| KR100806004B1 (ko) | 선택적 페록시좀 증식제 활성화 수용체 조절제 | |
| ES2364964T3 (es) | Derivados del ácido fenilbenzoico, procesos para su preparación, composiciones farmacéuticas que los comprenden y usos terapéuticos de los mismos. | |
| McIntyre et al. | Tesaglitazar |
